南美和中美人类疫苗佐剂市场预测至 2030 年 - 区域分析 - 按类型(颗粒佐剂、乳剂佐剂、组合佐剂及其他)、应用(流感、肝炎、人乳头瘤病毒 (HPV) 及其他)和最终用户(制药和生物技术公司、CMO 和 CRO 及其他)划分

BMIRE00030544 | Pages: 91 | Pharmaceuticals | Jul 2024 | Type: Regional | Status: Published
2022 年,南美和中美洲人类疫苗佐剂市场价值为 6362 万美元,预计到 2030 年将达到 1.8534 亿美元;预计 2022 年至 2030 年的复合年增长率为 14.3%。

个性化疫苗上升趋势推动南美和中美洲人类疫苗佐剂市场发展

精准或个性化疫苗是南美和中美洲人类疫苗佐剂市场的一个日益增长的趋势。这些疫苗针对患者疾病的特定遗传或分子特征,有助于生产针对每个患者独特免疫反应量身定制的疫苗。该技术可以潜在地提高疫苗接种的有效性和安全性,从而引起人们对用于治疗癌症、传染病和自身免疫性疾病等疾病的个性化疫苗的兴趣增加。生产个性化疫苗需要能够增强对这些定制疫苗的免疫反应的佐剂。佐剂对于刺激免疫系统对疫苗特定抗原产生有针对性的强大反应至关重要。因此,对能够有效增强个性化疫苗免疫反应的佐剂的需求日益增加。近年来,人们非常重视研发工作,以识别和创造能够有效增加个性化疫苗免疫反应的佐剂。例如,2022 年 12 月,Moderna 和 Merck 宣布推出 mRNA-4157/V940,一种研究性个性化 mRNA 癌症疫苗,与 KEYTRUDA(R)(派姆单抗)联合使用。与单独使用 KEYTRUDA 相比,使用 mRNA-4157/V940 与 KEYTRUDA 联合进行辅助治疗可将复发或死亡风险降低 44%。监管机构和医疗保健组织认识到个性化疫苗在改善公共卫生结果方面的潜力。因此,越来越多地开发能够有效改善个性化疫苗免疫反应的佐剂,从而提高疫苗的效力和安全性。这一趋势推动了南美和中美人用疫苗佐剂市场的大量创新和投资。

南美和中美人用疫苗佐剂市场概览

巴西是南美和中美最大的国家之一。根据巴西地理和统计研究所 (IBGE) 的数据,巴西拥有统一的医疗保健系统 (SUS),可为大约 72% 的人口提供医疗服务。SUS 提供免费药物,并促进主要针对老年人和儿童的国家疫苗接种计划。据国际贸易管理局称,巴西公共实验室和大学在诊断试剂盒、药物和疫苗的研究和开发中发挥着关键作用。

根据 2020 年 10 月发布的全球疾病负担研究,巴西各种慢性病和传染病的患病率不断上升,例如结核病、中风、流感、慢性阻塞性肺病 (COPD)、阿尔茨海默病和糖尿病。同样,根据疾病预防控制中心的数据,蚊媒疾病(基孔肯雅病、登革热、疟疾、黄热病和寨卡病毒)在巴西流行。因此,由于巴西的疾病负担不断增加,人用疫苗佐剂的应用将会增加。

医疗支出的增加和老年人口的增加正在推动人用疫苗佐剂的发展。根据世界银行的数据,2020 年巴西的医疗支出占 GDP 的 10.31%,较 2015 年的 8.91% 大幅增加。此外,该国老年人口的增加使人们面临各种疾病和残疾的高风险。经合组织报告称,到 2050 年,巴西 21.9% 的人口预计将达到 65 岁及以上,较 2017 年的 8.9% 大幅增长。因此,老年人口、传染病患病率和医疗支出的增加将推动未来几年巴西人类疫苗佐剂市场的增长。

南美洲和中美洲人类疫苗佐剂市场收入及预测至 2030 年(百万美元)

南美洲和中美洲人类疫苗佐剂市场细分

南美洲和中美洲人类疫苗佐剂市场分为类型、应用、最终用户和国家。

根据类型,南美洲和中美洲人类疫苗佐剂市场分为颗粒佐剂、乳剂佐剂、组合佐剂和其他。颗粒佐剂部分在 2022 年占据了最大的市场份额。

就应用而言,南美和中美人类疫苗佐剂市场分为流感、肝炎、人乳头瘤病毒 (HPV) 等。流感部分在 2022 年占据了最大的市场份额。

按最终用户划分,南美和中美人类疫苗佐剂市场细分为制药和生物技术公司、CMO 和 CRO 等。制药和生物技术公司部分在 2022 年占据了最大的市场份额。

按国家/地区划分,南美和中美人类疫苗佐剂市场细分为巴西、阿根廷和南美和中美洲其他地区。 2022 年,巴西占据了南美和中美人类疫苗佐剂市场的主导份额。

诺华公司 (Novartis AG)、CSL 有限公司、Seppic SA、Croda International Plc、Novavax Inc 和 Phibro Animal Health Corp 是南美和中美人类疫苗佐剂市场的一些领先公司。

TABLE OF CONTENTS

 

1. Introduction

1.1 The Insight Partners Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. South & Central America Human Vaccine Adjuvants Market - Key Market Dynamics

4.1 South & Central America Human Vaccine Adjuvants Market - Key Market Dynamics

4.2 Market Drivers

4.2.1 Rising Prevalence of Chronic Diseases

4.2.2 Growing Focus on Immunization Programs

4.3 Market Restraints

4.3.1 Manufacturing Complexities and Regulatory Challenges

4.4 Market Opportunities

4.4.1 Growing Pharmaceutical Industry

4.5 Future Trends

4.5.1 Rising Trend of Personalized Vaccines

4.6 Impact of Drivers and Restraints:

5. Human Vaccine Adjuvants Market - South & Central America Market Analysis

5.1 South & Central America Human Vaccine Adjuvants Market Revenue (US$ Million), 2020 - 2030

5.2 South & Central America Human Vaccine Adjuvants Market Forecast Analysis

6. South & Central America Human Vaccine Adjuvants Market Analysis - by Type

6.1 Particulate Adjuvant

6.1.1 Overview

6.1.2 Particulate Adjuvant: South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

6.2 Emulsion Adjuvant

6.2.1 Overview

6.2.2 Emulsion Adjuvant: South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

6.3 Combination Adjuvant

6.3.1 Overview

6.3.2 Combination Adjuvant: South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

6.4 Others

6.4.1 Overview

6.4.2 Others: South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

7. South & Central America Human Vaccine Adjuvants Market Analysis - by Application

7.1 Influenza

7.1.1 Overview

7.1.2 Influenza: South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

7.2 Hepatitis

7.2.1 Overview

7.2.2 Hepatitis: South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

7.3 Human papilloma virus (HPV)

7.3.1 Overview

7.3.2 Human papilloma virus (HPV): South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

7.4 Others

7.4.1 Overview

7.4.2 Others: South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

8. South & Central America Human Vaccine Adjuvants Market Analysis - by End User

8.1 Pharmaceutical and Biotechnology Companies

8.1.1 Overview

8.1.2 Pharmaceutical and Biotechnology Companies: South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

8.2 CMOs and CROs

8.2.1 Overview

8.2.2 CMOs and CROs: South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

8.3 Others

8.3.1 Overview

8.3.2 Others: South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

9. South & Central America Human Vaccine Adjuvants Market - Country Analysis

9.1 South & Central America

9.1.1 South & Central America Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)

9.1.1.1 Brazil Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

9.1.1.1.1 Brazil Human Vaccine Adjuvants Market Breakdown, by Type

9.1.1.1.2 Brazil Human Vaccine Adjuvants Market Breakdown, by Application

9.1.1.1.3 Brazil Human Vaccine Adjuvants Market Breakdown, by End User

9.1.1.2 Argentina Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

9.1.1.2.1 Argentina Human Vaccine Adjuvants Market Breakdown, by Type

9.1.1.2.2 Argentina Human Vaccine Adjuvants Market Breakdown, by Application

9.1.1.2.3 Argentina Human Vaccine Adjuvants Market Breakdown, by End User

9.1.1.3 Rest of South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

9.1.1.3.1 Rest of South & Central America Human Vaccine Adjuvants Market Breakdown, by Type

9.1.1.3.2 Rest of South & Central America Human Vaccine Adjuvants Market Breakdown, by Application

9.1.1.3.3 Rest of South & Central America Human Vaccine Adjuvants Market Breakdown, by End User

10. Industry Landscape

10.1 Overview

11. Company Profiles

11.1 Novartis AG

11.1.1 Key Facts

11.1.2 Business Description

11.1.3 Products and Services

11.1.4 Financial Overview

11.1.5 SWOT Analysis

11.1.6 Key Developments

11.2 CSL Ltd

11.2.1 Key Facts

11.2.2 Business Description

11.2.3 Products and Services

11.2.4 Financial Overview

11.2.5 SWOT Analysis

11.2.6 Key Developments

11.3 Seppic SA

11.3.1 Key Facts

11.3.2 Business Description

11.3.3 Products and Services

11.3.4 Financial Overview

11.3.5 SWOT Analysis

11.3.6 Key Developments

11.4 Croda International Plc

11.4.1 Key Facts

11.4.2 Business Description

11.4.3 Products and Services

11.4.4 Financial Overview

11.4.5 SWOT Analysis

11.4.6 Key Developments

11.5 Novavax Inc

11.5.1 Key Facts

11.5.2 Business Description

11.5.3 Products and Services

11.5.4 Financial Overview

11.5.5 SWOT Analysis

11.5.6 Key Developments

11.6 Phibro Animal Health Corp

11.6.1 Key Facts

11.6.2 Business Description

11.6.3 Products and Services

11.6.4 Financial Overview

11.6.5 SWOT Analysis

11.6.6 Key Developments

12. Appendix

12.1 About The Insight Partners

12.2 Glossary of Terms

List of Tables

Table 1. South & Central America Human Vaccine Adjuvants Market Segmentation

Table 2. South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

Table 3. South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Type

Table 4. South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Application

Table 5. South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by End User

Table 6. Brazil Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type

Table 7. Brazil Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application

Table 8. Brazil Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User

Table 9. Argentina Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type

Table 10. Argentina Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application

Table 11. Argentina Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User

Table 12. Rest of South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Type

Table 13. Rest of South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application

Table 14. Rest of South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by End User

Table 15. Recent Growth Strategies in the Human Vaccine Adjuvants Market

Table 16. Glossary of Terms, Human Vaccine Adjuvants Market

List of Figures

Figure 1. South & Central America Human Vaccine Adjuvants Market Segmentation, by Country

Figure 2. Impact Analysis of Drivers and Restraints

Figure 3. South & Central America Human Vaccine Adjuvants Market Revenue (US$ Million), 2022 - 2030

Figure 4. South & Central America Human Vaccine Adjuvants Market Share (%) - by Type (2022 and 2030)

Figure 5. Particulate Adjuvant: South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

Figure 6. Emulsion Adjuvant: South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

Figure 7. Combination Adjuvant: South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

Figure 8. Others: South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

Figure 9. South & Central America Human Vaccine Adjuvants Market Share (%) - by Application (2022 and 2030)

Figure 10. Influenza: South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

Figure 11. Hepatitis: South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

Figure 12. Human papilloma virus (HPV): South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

Figure 13. Others: South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

Figure 14. South & Central America Human Vaccine Adjuvants Market Share (%) - by End User (2022 and 2030)

Figure 15. Pharmaceutical and Biotechnology Companies: South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

Figure 16. CMOs and CROs: South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

Figure 17. Others: South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

Figure 18. South & Central America Human Vaccine Adjuvants Market Breakdown, by Key Countries - Revenue (2022) (US$ Million)

Figure 19. South & Central America Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)

Figure 20. Brazil Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)

Figure 21. Argentina Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)

Figure 22. Rest of South & Central America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)

1. Novartis AG 
2. CSL Ltd 
3. Seppic SA 
4. Croda International Plc 
5. Novavax Inc 
6. Phibro Animal Health Corp 

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America human vaccine adjuvants market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the South & Central America human vaccine adjuvants market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the South & Central America human vaccine adjuvants market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.
Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$3550
$2840
Site License
$4550
$3640
Enterprise License
$5550
$4440